A year of Tigit (and Alzheimer’s) for Roche
With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Abbott and J&J start the year from different places
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
Glaxo adds flesh to its oncology ambitions
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Novartis hopes Kymriah acceleration can save its CAR
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
